Relmada Therapeutics, Inc. (RLMD) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Relmada Therapeutics, Inc. (RLMD) Healthcare & Pipeline Overview

Relmada Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in central nervous system (CNS) disorders, primarily focusing on its lead product candidate, Esmethadone (REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist currently in Phase 3 trials for major depressive disorder, positioning it within the competitive pharmaceutical landscape.

What Is the Investment Thesis for RLMD?

Relmada Therapeutics presents a focused investment opportunity centered on Esmethadone (REL-1017), its lead product candidate targeting major depressive disorder (MDD). The ongoing Phase 3 clinical trials represent a critical value driver; positive results could lead to regulatory approval and subsequent commercialization. The company's market capitalization of $427M reflects the potential upside associated with successful drug development in a high-need therapeutic area. Key risks include clinical trial failures, regulatory hurdles, and competition from existing and emerging treatments for MDD. The company's relatively small size and limited resources also pose operational challenges. Successful commercialization of Esmethadone could drive significant revenue growth, while failure to achieve positive clinical outcomes could negatively impact the stock price.

Based on FMP financials and quantitative analysis

RLMD Key Highlights

Esmethadone (REL-1017) is in Phase 3 clinical trials for major depressive disorder (MDD), representing a key milestone.

• Relmada Therapeutics has a market capitalization of $427M, reflecting investor expectations for its drug development pipeline.
• The company focuses on central nervous system (CNS) diseases, a therapeutic area with significant unmet needs.
• Relmada Therapeutics was founded in 2004, demonstrating a history of research and development in the biotechnology sector.
• The company has a beta of 0.45, indicating lower volatility compared to the overall market.

Who Are RLMD's Competitors?

RLMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are RLMD's Key Strengths?

Novel drug candidate (Esmethadone) with a unique mechanism of action.

• Phase 3 clinical trials underway, indicating advanced stage of development.
• Focus on a significant unmet need in the treatment of major depressive disorder.
• Relatively low beta (0.45) suggesting lower volatility.

What Are RLMD's Weaknesses?

Clinical-stage company with no currently marketed products.

• Limited financial resources compared to larger pharmaceutical companies.
• Small number of employees (17), potentially limiting operational capacity.
• Reliance on the success of a single lead product candidate.

What Could Drive RLMD Stock Higher?

RLMD catalyst: Data readout from the ongoing Phase 3 clinical trials of Esmethadone for major depressive disorder.

• Potential regulatory submission for Esmethadone to the FDA.
• Enrollment and progress in the Phase 3 clinical trials.
• Potential partnership or licensing agreements for Esmethadone.

What Are the Key Risks for RLMD?

Negative return on equity (-71.2%) — the business is not currently generating profit on shareholder capital.

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Failure of clinical trials to meet primary endpoints.
• Regulatory delays or rejection of Esmethadone's approval.
• Competition from other pharmaceutical companies in the antidepressant market.
• Dependence on the success of a single lead product candidate.
• Difficulty in securing additional funding for research and development.

What Are the Growth Opportunities for RLMD?

• Successful completion of Phase 3 clinical trials for Esmethadone in MDD represents a significant growth opportunity. Positive results would pave the way for regulatory approval and commercial launch, potentially capturing a substantial share of the MDD market, estimated to reach $15.98 billion by 2027. The timeline for commercialization depends on the clinical trial outcomes and regulatory review process, but approval could occur within the next 2-3 years. Relmada's competitive advantage lies in Esmethadone's novel mechanism of action as an NMDA receptor antagonist.
• Expansion of Esmethadone's clinical development program to include other CNS disorders, such as bipolar disorder or post-traumatic stress disorder (PTSD), could unlock additional growth opportunities. These indications represent significant unmet needs and potential market expansion. The timeline for initiating clinical trials in these areas depends on the availability of resources and the prioritization of development programs. Success in these indications would diversify Relmada's product pipeline and reduce its reliance on MDD.
• Strategic partnerships with larger pharmaceutical companies for the commercialization of Esmethadone could accelerate market penetration and maximize revenue potential. Partnering with an established player would provide access to a broader sales force, marketing expertise, and distribution network. The timing of such partnerships depends on the progress of clinical development and the attractiveness of Esmethadone to potential partners. These partnerships could provide significant upfront payments and milestone payments, as well as royalties on future sales.
• Development of a proprietary formulation or delivery system for Esmethadone could enhance its therapeutic profile and extend its patent life. A novel formulation could improve bioavailability, reduce side effects, or simplify administration. The timeline for developing and testing a new formulation depends on the complexity of the formulation and the regulatory requirements. A successful formulation could provide a competitive advantage and protect Esmethadone from generic competition.
• Geographic expansion into international markets, such as Europe and Asia, could significantly increase the addressable market for Esmethadone. These markets represent substantial growth opportunities, particularly in countries with high rates of depression and limited access to effective treatments. The timeline for international expansion depends on regulatory approvals and market access considerations in each country. Successful expansion would require establishing local partnerships and navigating diverse regulatory landscapes.

What Threats Does RLMD Face?

• Failure of clinical trials to demonstrate efficacy or safety.
• Regulatory hurdles and delays in obtaining drug approval.
• Competition from existing and emerging treatments for major depressive disorder.
• Patent expiration and generic competition.

What Are RLMD's Competitive Advantages?

• Patent protection for Esmethadone (REL-1017) provides a period of market exclusivity.
• Novel mechanism of action (NMDA receptor antagonist) differentiates Esmethadone from existing treatments.
• Clinical trial data demonstrating efficacy and safety can create a competitive advantage.
• Established relationships with key opinion leaders and researchers in the field of CNS disorders.

What Does RLMD Do?

Relmada Therapeutics, Inc., founded in 2004 and headquartered in Coral Gables, Florida, is a clinical-stage biotechnology company dedicated to developing innovative therapies for central nervous system (CNS) diseases and other disorders. The company's primary focus is on addressing unmet needs in the treatment of major depressive disorder (MDD) and other neurological conditions. Relmada's lead product candidate, Esmethadone (d-methadone, dextromethadone, or REL-1017), is a novel chemical entity and an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone is currently undergoing Phase 3 clinical trials as both an adjunctive and monotherapy treatment for adults suffering from MDD. This molecule represents a potentially significant advancement in the treatment of depression due to its novel mechanism of action and promising clinical data. The company's strategic focus is on advancing Esmethadone through clinical development and ultimately seeking regulatory approval to bring this therapy to market. Relmada operates with a lean structure, employing 17 individuals, allowing for focused execution of its clinical programs. The company's success hinges on the positive outcomes of its ongoing clinical trials and its ability to navigate the regulatory landscape effectively.

What Products and Services Does RLMD Offer?

• Relmada Therapeutics develops products for central nervous system (CNS) diseases.
• They focus on creating new treatments for major depressive disorder (MDD).
• Their lead product, Esmethadone (REL-1017), is in Phase 3 clinical trials.
• Esmethadone is a novel N-methyl-D-aspartate (NMDA) receptor antagonist.
• The company aims to provide alternative therapies for unmet needs in CNS disorders.
• Relmada conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
• They seek regulatory approval for their products to bring them to market.

How Does RLMD Make Money?

• Relmada Therapeutics focuses on the research and development of novel pharmaceutical products.
• Their business model relies on advancing drug candidates through clinical trials and obtaining regulatory approval.
• They aim to commercialize their products either independently or through strategic partnerships.
• Revenue generation is dependent on successful drug development and market launch.

What Industry Does RLMD Operate In?

Relmada Therapeutics operates within the biotechnology industry, which is characterized by high levels of research and development, regulatory scrutiny, and competition. The market for CNS therapeutics, particularly for major depressive disorder, is substantial and growing, driven by increasing prevalence and unmet treatment needs. The competitive landscape includes established pharmaceutical companies and other biotechnology firms developing novel treatments for depression. Relmada's success depends on its ability to differentiate Esmethadone from existing therapies and demonstrate superior efficacy and safety. The biotechnology industry is subject to significant regulatory oversight, with the FDA playing a critical role in drug approval and commercialization.

Who Are RLMD's Key Customers?

• Patients suffering from major depressive disorder (MDD) are the primary target customer group.
• Healthcare providers, including psychiatrists and primary care physicians, are key prescribers.
• Hospitals and clinics that treat patients with CNS disorders are potential customers.
• Pharmaceutical distributors and wholesalers facilitate the distribution of Relmada's products.

Relmada Therapeutics, Inc. Financial Trajectory

Relmada Therapeutics, Inc. (RLMD) reported $0 in revenue for Q2 FY2026, based on the latest filing compared to the prior quarter. The company recorded a net loss of $12.9M, with diluted EPS of $-0.11. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, RLMD averaged $-0.23 in diluted EPS.

Company Profile

Relmada Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Coral Gables, US. The company is led by CEO Sergio Traversa. RLMD has traded publicly since 2014.

How Relmada Therapeutics, Inc. Is Valued

Relmada Therapeutics, Inc. carries a market capitalization of $427M, placing it in the small-cap category. Analyst price targets span from $10.00 to $12.00, with a consensus of $11.00. At the current price of $4.07, that implies approximately 170% upside potential. Relative to its peer group, RLMD's quantitative score of 61/100 is below the peer average of 83/100.

Return on equity for Relmada Therapeutics, Inc. stands at -71.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -25.0%, showing how much profit it generates from its asset base. Its free cash flow yield is -6.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 18.26 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -10.6%, the inverse of the P/E and a quick read on earnings relative to price.

Relmada Therapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 16.38 places it in the safe zone, indicating low near-term bankruptcy risk.

Relmada Therapeutics, Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 103.3% below estimates on average.

RLMD Financials

RLMD Latest News

RLMD Analyst Consensus

RLMD MoonshotScore

What Investors Ask About Relmada Therapeutics, Inc. (RLMD) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources